因为顺铂会损害肾脏和耳蜗，有肾脏问题或听力损失的患者通常不适合服用这种药物。寻找替代方案一直具有挑战性。俄克拉荷马大学放射肿瘤学家Christina Henson医学博士是《柳叶刀》杂志最近发表的一篇文章的合著者，该文章测试了免疫治疗药物durvalumab联合放射治疗作为顺铂替代品的有效性。Durvalumab与另一种免疫治疗药物西妥昔单抗进行了比较。

Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 (GLOBE ...

智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验 ...

The time of day of immunotherapy infusions does appear to affect patient outcomes. But convincing the wider oncology ...

最近，阿斯利康还发布了关于度伐利尤单抗围手术期治疗的新研究成果，显示该药物在肌层浸润性膀胱癌患者中显著改善了无事件生存期和总生存期。这一突破为该药物的全球开发提供了新的动力，让我们期待它在更多癌症领域的应用。

智通财经APP获悉，阿斯利康（AstraZeneca，AZN.US）公司今日公布了3期临床试验NIAGARA的事后探索性亚组分析结果。分析显示，其重磅免疫疗法Imfinzi（durvalumab）围手术期治疗方案，与新辅助化疗联用，在肌层浸润性膀胱癌（MIBC）患者中改善了无事件生存期（EFS）和总生存期（OS），无论患者是否达到病理学完全缓解（pCR） ...

Get Instant Summarized Text (Gist) Radiation combined with the immune checkpoint inhibitors durvalumab and tremelimumab shows ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Use the least expensive option of the available treatments (including durvalumab and atezolizumab). Take account of administration costs, dosages, price per dose and commercial arrangements. If the ...

Durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin is indicated for 'the first-line treatment of adults with extensive-stage small cell lung cancer'.